Literature DB >> 9426051

Precise microdissection of human prostate cancers reveals genotypic heterogeneity.

C A Macintosh1, M Stower, N Reid, N J Maitland.   

Abstract

To determine the incidence of genetic heterogeneity in primary prostate cancer, we have microdissected 125 tumor and mesenchymal foci from 18 patient biopsies and analyzed the DNA for loss of heterozygosity using PCR microsatellite markers. In 100% of patients with genetic lesions on chromosome 8p, there was evidence for intratumoral genetic heterogeneity. There was also a low but significant incidence of loss of heterozygosity in mesenchymal tissue. Our results show that phenotypically similar tumor foci can have different genotypes and provide evidence for the multifocality of tumor development in the prostate.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9426051

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Evidence of chromosomal instability in prostate cancer determined by spectral karyotyping (SKY) and interphase fish analysis.

Authors:  B Beheshti; P C Park; J M Sweet; J Trachtenberg; M A Jewett; J A Squire
Journal:  Neoplasia       Date:  2001 Jan-Feb       Impact factor: 5.715

Review 2.  Interaction of prostate carcinoma-associated fibroblasts with human epithelial cell lines in vivo.

Authors:  Takeshi Sasaki; Omar E Franco; Simon W Hayward
Journal:  Differentiation       Date:  2017-07-20       Impact factor: 3.880

3.  In vitro models of pancreatic cancer for translational oncology research.

Authors:  Georg Feldmann; Sherri Rauenzahn; Anirban Maitra
Journal:  Expert Opin Drug Discov       Date:  2009-04-01       Impact factor: 6.098

4.  Cells Comprising the Prostate Cancer Microenvironment Lack Recurrent Clonal Somatic Genomic Aberrations.

Authors:  Daniella Bianchi-Frias; Ryan Basom; Jeffrey J Delrow; Ilsa M Coleman; Olga Dakhova; Xiaoyu Qu; Min Fang; Omar E Franco; Nolan G Ericson; Jason H Bielas; Simon W Hayward; Lawrence True; Colm Morrissey; Lisha Brown; Neil A Bhowmick; David Rowley; Michael Ittmann; Peter S Nelson
Journal:  Mol Cancer Res       Date:  2016-01-11       Impact factor: 5.852

5.  The onset and extent of genomic instability in sporadic colorectal tumor progression.

Authors:  D L Stoler; N Chen; M Basik; M S Kahlenberg; M A Rodriguez-Bigas; N J Petrelli; G R Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

6.  Genomic homogeneity in fibrolamellar carcinomas.

Authors:  Y Sirivatanauksorn; V Sirivatanauksorn; N R Lemoine; R C Williamson; B R Davidson
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

Review 7.  [Focal prostate cancer therapy: capabilities, limitations and prospects].

Authors:  D Baumunk; A Blana; R Ganzer; T Henkel; J Köllermann; A Roosen; S Machtens; G Salomon; L Sentker; U Witzsch; K U Köhrmann; M Schostak
Journal:  Urologe A       Date:  2013-04       Impact factor: 0.639

Review 8.  Tumor heterogeneity: causes and consequences.

Authors:  Andriy Marusyk; Kornelia Polyak
Journal:  Biochim Biophys Acta       Date:  2009-11-18

9.  Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.

Authors:  Lei Wei; Jianmin Wang; Erika Lampert; Simon Schlanger; Adam D DePriest; Qiang Hu; Eduardo Cortes Gomez; Mitsuko Murakam; Sean T Glenn; Jeffrey Conroy; Carl Morrison; Gissou Azabdaftari; James L Mohler; Song Liu; Hannelore V Heemers
Journal:  Eur Urol       Date:  2016-07-21       Impact factor: 20.096

10.  Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.

Authors:  Wennuan Liu; Sari Laitinen; Sofia Khan; Mauno Vihinen; Jeanne Kowalski; Guoqiang Yu; Li Chen; Charles M Ewing; Mario A Eisenberger; Michael A Carducci; William G Nelson; Srinivasan Yegnasubramanian; Jun Luo; Yue Wang; Jianfeng Xu; William B Isaacs; Tapio Visakorpi; G Steven Bova
Journal:  Nat Med       Date:  2009-04-12       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.